• 1
    Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis (9th edition): American College of Chest Physicians Evidence- Based Practice Guidelines. Chest2012; 2 (Suppl.): e24S43S.
  • 2
    Douketis JD, Spyropoulos AC, Spencer FA, et al.Perioperative management of antithrombotic therapy (9th edition): American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest2012; 2 (Suppl.): e326S50S.
  • 3
    Douketis JD, Woods K, Foster GA, Crowther MA. Bridging anticoagulation with low molecular weight heparin after interruption of warfarin therapy is associated with a residual anticoagulant effect prior to surgery. Thrombosis and Haemostasis2005; 94: 52831.
  • 4
    Keeling D, Baglin T, Tait C, et al.Guidelines on oral anticoagulation with warfarin- fourth edition. British Journal of Haematology2011; 154: 31124.
  • 5
    Chan KL, Summerhayes RG, Ignjatovic V, Horton SB, Monagle PT. Reference values for kaolin-activated thromboelastography in healthy children. Anesthesia and Analgesia2007; 105: 16103.
  • 6
    Douketis JD, Berger PB, Dunn AS, et al.The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest2008; 6 (Suppl.): 299S339S.
  • 7
    Vera-Llonch M, Hagiwara M, Oster G. Clinical and economic consequences of bleeding following major orthopaedic surgery. Thrombosis Research2006; 117: 56977.
  • 8
    Spyropoulos AC, Turpie AG, Dunn AS, et al.Perioperative bridging therapy with unfractionated heparin or low molecular weight heparin in patients with mechanical prosthetic heart valves on long-term oral anticoagulants (from the REGIMEN registry). American Journal of Cardiology2008; 102: 8839.
  • 9
    Bounameaux H, de Moerloose P. Is laboratory monitoring of low-molecular-weight-heparin therapy necessary? No. Journal of Thrombosis and Haemostasis2004; 2: 5514.
  • 10
    Simons R, Mallett SV. Use of thromboelastography to demonstrate persistent anticoagulation after stopping enoxaparin. Anaesthesia2007; 62: 11758.
  • 11
    Klein SM, Slaughter TF, Vail PT, et al.Thromboelastography as a perioperative measure of anticoagulation resulting from low molecular weight heparin: a comparison with anti-Xa concentrations. Anesthesia and Analgesia2000; 91: 10915.
  • 12
    Backe SK, Lyons GR. High-dose tinzaparin in pregnancy and the need for urgent delivery. British Journal of Anaesthesia2002; 89: 3314.
  • 13
    Jackson GNB, Ashpole KJ, Yentis SM. The TEG ® vs the ROTEM® thromboelastography/thromboelastometry systems. Anaesthesia2009; 64: 2125.
  • 14
    Van Ryn- Mckenna J, Cai L, Ofosu FA, Hirsh J, Buchanan MR. Neutralization of enoxaparine- induced bleeding by protamine sulfate. Thrombosis and Haemostasis1990; 63: 2714.
  • 15
    Monagle P, Chan AKC, Goldenberg NA, et al.Antithrombotic therapy in neonates and children. Antithrombotic therapy and prevention of thrombosis: 9th edition: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest2012; 141 (2 Suppl.): 737s801s.
  • 16
    Trame MN, Mitchell L, Krümpel A, Male C, Hempel G, Norwal-Göttl U. Population pharmacokinetics of enoxaparin in infants, children and adolescents during secondary thromboembolic prophylaxis: a cohort study. Journal of Thrombosis and Haemostasis2010; 8: 19508.
  • 17
    Ignjatovic V, Najid S, Newall F, Summerhayes R, Monagle P. Dosing and monitoring of enoxaparin (low molecular weight heparin) therapy in children. British Journal of Haematology2010; 149: 7348.
  • 18
    Hiippala ST, Myllyla GJ, Vahtera EM. Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates. Anesthesia and Analgesia1995; 81: 3605.
  • 19
    Bolliger D, Szlam F, Molinaro RJ, Rahe-Meyer N, Levy JH, Tanaka KA. Finding the optimal concentration range for fibrinogen replacement after severe haemodilution: an in-vitro model. British Journal of Anaesthesia2009; 102: 7939.
  • 20
    Levy JH, Szlam F, Tanaka KA, Sniecienski RM. Fibrinogen and hemostasis: a primary hemostatic target for the management of acquired bleeding. Anesthesia and Analgesia2012; 114: 26174.
  • 21
    Rossaint R, Bouillon B, Cerny V, et al.Management of bleeding following major trauma: an updated European guideline. Critical Care2010; 14: R52.
  • 22
    Charbit B, Mandelbrot L, Samain E, et al.The decrease of fibrinogen is an early predictor of the severity of postpartum haemorrhage. Journal of Thrombosis and Haemostasis2007; 5: 26673.
  • 23
    Fenger-Eriksen C, Jensen TM, Kristensen BS, et al.Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo-controlled clinical trial. Journal of Thrombosis and Haemostasis2009; 7: 795802.
  • 24
    Schulte A, Clark M. The effect of line flush heparin contamination on thromboelastograph trace analysis. Anaesthesia2008; 63: 13812.